UBS sets a USD 52.00 target for CRISPR Therapeutics stock

Published on 10/17/2026 at 21:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 10.18 million. CRISPR Therapeutics stock stood at USD 49.25 on October 16, 2026, down 4.41 percent on Nasdaq.

Analyst view and upcoming report

On October 14, 2026, UBS began coverage with a USD 52.00 target for CRISPR Therapeutics.
Second-quarter 2026 revenue reached USD 10.18 million, while net loss was USD 91.15 million.
CRISPR Therapeutics stock last stood at USD 49.25 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 4.41 percent versus the prior close of USD 51.52.
The next reported earnings date is November 4, 2026.

CRSP, CH0334081137, Illustration mit AI erstellt.

On October 14, 2026, UBS initiated coverage of CRISPR Therapeutics with a Neutral rating and a USD 52.00 price target, placing the target 5.58 percent above the Nasdaq price of USD 49.25. The report cited the approved Casgevy therapy but also pointed to delays in pipeline updates, according to Markets Insider. Second-quarter revenue reached USD 10.18 million, while net loss was USD 91.15 million, according to Simply Wall St. CRISPR Therapeutics stock last stood at USD 49.25 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 4.41 percent versus the Nasdaq prior close of USD 51.52.

Revenue improved in the second quarter

The second-quarter 2026 revenue figure was 37.00 percent above the analyst estimate cited by Simply Wall St. The USD 91.15 million net loss narrowed from USD 122.93 million in the first quarter of 2026, while diluted loss per share improved from USD 1.28 to USD 0.94.

Stock sits above its yearly low

At USD 49.25 on October 16, 2026, the stock was USD 5.13 above its 52-week low of USD 44.12 and USD 25.81 below its 52-week high of USD 75.06. Trading volume was 1,285,765 shares, compared with an average volume of 1,579,717 shares, on October 16, 2026.

Valuation and November 4

CRISPR Therapeutics had a market capitalization of USD 4.8 billion and a price-to-earnings ratio of minus 10.35 as of October 16, 2026. The next earnings report is scheduled for November 4, 2026, according to FXEmpire.

Comparison with peers

CRSP (Nasdaq, USD): minus 4.41 percent, P/E -10.35, market capitalization USD 4.8 billion.
Intellia Therapeutics (Nasdaq, USD): plus 0.71 percent, P/E -3.40, market capitalization USD 1.6 billion.
Editas Medicine (Nasdaq, USD): minus 3.69 percent, P/E -3.14, market capitalization USD 360.9 million.

What matters for the stock

The figures frame a biotechnology company with improving quarterly revenue but continuing losses. UBS's USD 52.00 target sits above the latest Nasdaq price, while the upcoming November report provides the next dated test for revenue and pipeline execution.